Polyethylene Glycol Safety in Children
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05424757 |
Recruitment Status :
Recruiting
First Posted : June 21, 2022
Last Update Posted : October 13, 2023
|
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date | June 15, 2022 | ||||||
First Posted Date | June 21, 2022 | ||||||
Last Update Posted Date | October 13, 2023 | ||||||
Actual Study Start Date | September 30, 2022 | ||||||
Estimated Primary Completion Date | June 2024 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures |
|
||||||
Original Primary Outcome Measures |
|
||||||
Change History | |||||||
Current Secondary Outcome Measures | Not Provided | ||||||
Original Secondary Outcome Measures | Not Provided | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title | Polyethylene Glycol Safety in Children | ||||||
Official Title | Quantitative Analysis of Selected PEG 3350 Components and Metabolites in Children's Plasma and Urine | ||||||
Brief Summary | The primary objective is to measure levels of selected PEG 3350 components and metabolites in the blood and urine of children who are already taking PEG 3350 compared to children who are not taking PEG 3350. Changes to medical therapy are not recommended as part of this study. |
||||||
Detailed Description | For subjects taking PEG 3350, blood and urine will be collected 1.5 to 4 hours after subjects take PEG 3350. For subjects who are not taking PEG 3350, the same PEG 3350 components and metabolites will be measured in blood and urine. PEG 3350 containing medicines from study subjects will be analyzed for the same PEG 3350 components and metabolites. A stool specimen will be collected for future studies. Additional data will be obtained from:
|
||||||
Study Type | Observational [Patient Registry] | ||||||
Study Design | Observational Model: Case-Control Time Perspective: Cross-Sectional |
||||||
Target Follow-Up Duration | 1 Day | ||||||
Biospecimen | Retention: Samples Without DNA Description:
|
||||||
Sampling Method | Non-Probability Sample | ||||||
Study Population | Study population will be selected from children cared for at The Children's Hospital of Philadelphia. | ||||||
Condition |
|
||||||
Intervention | Drug: PEG 3350
Data and biospecimens will be collected from two groups of children:
No changes to medicines are recommended as part of this study. |
||||||
Study Groups/Cohorts |
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status | Recruiting | ||||||
Estimated Enrollment |
250 | ||||||
Original Estimated Enrollment |
150 | ||||||
Estimated Study Completion Date | June 2024 | ||||||
Estimated Primary Completion Date | June 2024 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria | Group 1: Children who do not have bowel or nervous system disease, or neuropsychiatric symptoms. Inclusion criteria: Children less than 17 years old who have been taking PEG 3350 for at least one month. Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day currently recommended by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines (2). Preferences will be given to children taking at least 17 grams/day. Normal Physical and neurological development for age. Weight and height percentiles ≥ 5% and ≤ 95% for age. Exclusion criteria: Children with underlying bowel problems that might be expected to increase bowel permeability (are included in group 2). In this group we will specifically exclude children with: Diarrhea within the past month. Note that PEG 3350 may cause loose stool and this is often the intended therapeutic effect. Therefore, we will exclude children with presumed infectious diarrhea since this may alter gut permeability but will include children whose loose stool is attributed to PEG 3350. If loose or watery stool began after initiation of PEG 3350 or after an increase in PEG 3350 dose within prior 3 days, children may be enrolled for GROUP 1. Children whose stool had a recognized diarrhea causing pathogen within the past 4 months will be excluded since the time required to repair epithelial lining is not clear. Enteric pathogens that would prevent enrollment include Salmonella, Shigella, Campylobacter, Yersinia, E. Coli (enterotoxigenic, enteropathogenic, enteraggregative, enterohemorrhagic), Clostridum difficile, Rotavirus, Norovirus, Astrovirus, and other known or suspected diarrhea causing organisms. H. pylori infection since this causes a stomach inflammation. HIV infection since this may alter bowel permeability (17) and predispose to other types of infection Symptoms neurologic disease or dysfunction (since they will be enrolled in Group 3). Group 2: Children with problems that might increase intestinal epithelial permeability. Inclusion criteria: Children less than 17 years old who have been taking PEG 3350 for at least one month. Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day currently recommended by the NASPGHAN and ESPGHAN guidelines (2). Preferences will be given to children taking at 17 grams/day. c. Any of the following problems associated with increased bowel permeability:
Exclusion criteria: a. Children with neurologic or neuropsychiatric symptoms. These children will be enrolled in Group 3. Group 3: Children with underlying neurologic disease or with neuropsychiatric disorders or symptoms. Inclusion criteria: Children less than 17 years old who have been taking PEG 3350 for at least one month. Dose of PEG 3350 greater than or equal to 0.4 grams/kg/day currently recommended by the NASPGHAN and ESPGHAN guidelines (2). Preference will be given to children taking at least 17 grams/day. Any of the following problems with the nervous system:
Note: Included in Group 3 are children with cerebral palsy, neuronal migration defects, traumatic brain injury, hypoxic ischemic encephalopathy, seizure disorder, tics, migraine, clinical depression, anxiety disorder, obsessive-compulsive disorder, post-surgical brain injury, autism spectrum disorder as well as genetic defects that affect the nervous system (Cornelia de Lange, Rett Syndrome, Pelizaeus-Merzbacher disease, etc.). Any weight and height (i.e., no exclusions based on growth percentiles). Abnormalities in any organ including the bowel are acceptable. Exclusion criteria: a. There are no specific exclusion criteria. This is important since this group may be at the highest risk for PEG 3350 side effects. Group 4: Children who are not taking PEG 3350. We will enroll 75 children who are not taking PEG 3350. Inclusion and exclusion criteria for these children will be the same as those detailed above for children who are taking PEG 3350 except that they may not have taken PEG 3350 within the last month. Enrollment targets for Groups 1, 2 and 3:
|
||||||
Sex/Gender |
|
||||||
Ages | 0 Years to 16 Years (Child) | ||||||
Accepts Healthy Volunteers | Yes | ||||||
Contacts |
|
||||||
Listed Location Countries | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number | NCT05424757 | ||||||
Other Study ID Numbers | 14-011454 1R01FD005312-01 ( U.S. FDA Grant/Contract ) |
||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement |
|
||||||
Current Responsible Party | Children's Hospital of Philadelphia | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor | Children's Hospital of Philadelphia | ||||||
Original Study Sponsor | Same as current | ||||||
Collaborators | Food and Drug Administration (FDA) | ||||||
Investigators |
|
||||||
PRS Account | Children's Hospital of Philadelphia | ||||||
Verification Date | October 2023 |